Skip to main content

Axela Licenses Beckman's Universal Linker Capture Tech for Biomarker Validation

NEW YORK (GenomeWeb News) — Biomarker validation company Axela Biosensors has nonexclusively licensed Beckman Coulter’s Universal Linker Capture technology, the companies said today.
 
Axela plans to use the technology in conjunction with its dotLab sensors to allow users to define their own biomarker panels and to use either the Axela library of pre-conjugated antibodies or their own reagents with universal linkers.
 
Axela CEO Rocky Ganske added that using the technologies will “allow users to tag their own antibodies or draw from a library of existing markers to build combined assays with micromolar to picomolar sensitivity requirements."
 
Financial terms of the deal were not released.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.